The Takeda Pharmaceutical Co. and Frazier Healthcare Partners recently launched Outpost Medicine, a new company in the biopharmaceutical field that will focus on developing new treatment options for urologic and gynecologic diseases and disorders.
Takeda has allowed Outpost to use an exclusive license for the global development and commercialization of OP-233, which was previously known as TAK-233. The financial amount of the deal is undisclosed at this time. OP-233 is a product currently in its clinical stage that is being researched for the treatment of stress urinary incontinence.
Recently, Takeda has been focusing on the areas of oncology, gastroenterology and the central nervous system and the associated diseases that go along with each. The establishment of Outpost is a groundbreaking collaboration that will help develop a promising new medicine that will bring new treatment options to patients.
Takeda sees OP-233 asthe perfect new asset to form Outpost Medicine around. With a team made up of world-class employees leading the way and financial support from a premier group of investors, Takeda believes that Outpost possesses all of the necessities to become a leader in the development of urology and gynecology therapeutics.